Last reviewed · How we verify
BCI-540
BCI-540 is a small molecule that modulates the activity of GABA_A receptors.
BCI-540 is a small molecule that modulates the activity of GABA_A receptors. Used for Major depressive disorder, Generalized anxiety disorder.
At a glance
| Generic name | BCI-540 |
|---|---|
| Sponsor | BrainCells Inc. |
| Drug class | GABA_A receptor modulator |
| Target | GABA_A receptor |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 2 |
Mechanism of action
BCI-540 acts as a positive allosteric modulator of GABA_A receptors, enhancing the inhibitory effects of GABA. This mechanism is thought to contribute to its potential therapeutic effects in various neurological disorders.
Approved indications
- Major depressive disorder
- Generalized anxiety disorder
Common side effects
- Dizziness
- Headache
- Nausea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BCI-540 CI brief — competitive landscape report
- BCI-540 updates RSS · CI watch RSS
- BrainCells Inc. portfolio CI